Cariporide (HOE 642) attenuates leukocyte activation in ischemia and reperfusion

M Redlin1, J Werner, H Habazettl

  • 1Institute of Anesthesiology, Deutsches Herzzentrum Berlin, Germany.

Anesthesia and Analgesia
|December 1, 2001
PubMed

Insights

Cariporide (HOE 642) reduces myocardial ischemia/reperfusion (I/R) injury by inhibiting Na(+)/H(+) exchange. This study shows cariporide also decreases inflammation by reducing leukocyte adhesion and emigration, possibly via L-selectin shedding.

Area of Science:

  • Cardiovascular Science
  • Inflammation Research
  • Pharmacology

Background:

  • Myocardial ischemia/reperfusion (I/R) injury is exacerbated by postischemic inflammation.
  • Cariporide (HOE 642) is known to reduce cardiac myocyte cytosolic [Ca(2+)] by inhibiting Na(+)/H(+) exchange.
  • The anti-inflammatory effects of cariporide remain largely unexplored.

Purpose of the Study:

  • To investigate the potential of cariporide to modulate inflammatory responses.
  • To determine cariporide's effect on leukocyte L-selectin expression in vitro.
  • To assess cariporide's impact on leukocyte adhesion and emigration in vivo during reperfusion.

Main Methods:

  • Intravital videomicroscopy of rat cremaster muscle subjected to ischemia/reperfusion.
  • Quantification of leukocyte rolling, adhesion, and emigration.
  • Flow cytometry analysis of L-selectin expression on human leukocytes treated with cariporide.

Main Results:

  • Cariporide significantly reduced leukocyte rolling (approx. 35%) and adhesion (approx. 45%) post-reperfusion.
  • Leukocyte extravasation was markedly decreased (approx. 85%) by cariporide.
  • Cariporide enhanced L-selectin shedding from activated human leukocytes in vitro.

Conclusions:

  • Cariporide (HOE 642) attenuates postischemic inflammation by inhibiting Na(+)/H(+) exchange.
  • The drug reduces leukocyte adhesion and emigration in vivo.
  • Increased L-selectin shedding from leukocytes may be a key mechanism for cariporide's anti-inflammatory effects.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...